October 01, 2024
2 min watch
Save
VIDEO: Optogenetic therapy shows promise for inherited retinal dystrophies
Issue: November 10, 2024
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Paulo-Eduardo Stanga, MD, explains the principles and mechanisms of action of optogenetic gene therapy.
Nanoscope Therapeutics has developed therapies that use multi-characteristic opsin to resensitize the retina, showing promise for inherited retinal dystrophies (IRDs) and geographic atrophy.
“This is not science fiction — this is a reality. We expect this therapy to become commercially available for IRDs sometime next year,” Stanga said.
Published by:
Sources/Disclosures
Collapse
Source:
Stanga P. Optogenetic therapies for IRDs. Presented at: Euretina congress; Sept. 19-22, 2024; Barcelona, Spain.
Disclosures:
Stanga reports consulting for Nanoscope Therapeutics.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.